Premium
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real‐world data from a large healthcare provider
Author(s) -
Weil C.,
Mehta D.,
Koren G.,
Pinsky B.,
Samp J. C.,
Chodick G.,
Shalev V.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12800
Subject(s) - ombitasvir , dasabuvir , paritaprevir , medicine , ritonavir , ribavirin , hepatitis c , regimen , population , hepatitis c virus , viral load , virology , human immunodeficiency virus (hiv) , virus , environmental health , antiretroviral therapy
Summary Treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin ( OP rD ± RBV ), was the first interferon‐free direct‐acting antiviral for hepatitis C virus ( HCV ) introduced to Israel's national basket of health services in February 2015. Patients with HCV genotype 1 ( GT 1) and advanced fibrosis (F3‐F4) were eligible for treatment in 2015. This study aimed to characterize patients initiating OP rD ± RBV and assess sustained virological response ( SVR ). A retrospective cohort study was performed using the database of Maccabi Healthcare Services ( MHS ), a 2‐million‐member health plan in Israel. The study population included adults who initiated OP rD ± RBV through December 2015 per health basket criteria. A gap in medication fills (>14 days between a fill's run‐out and the next fill) was used to estimate adherence. SVR was defined by the viral tests at least 12‐week post‐treatment. The study population consisted of 403 patients (56.3% male), with a mean age of 60.7 years ( SD 11.0). Overall, 71.0% were naïve to prior HCV treatment, and 95.6% were treated with a 12‐week regimen. A total of 348 patients (86.4%) completed the regimen in the usual time frame (highly adherent), whereas 8.2% completed with a gap, and 4.7% purchased less than the recommended dose. SVR rates overall and among highly adherent patients were 395/403 (98.0%; 95% CI 96.1‐99.1) and 346/348 (99.4%; 95% CI 97.9‐99.9), respectively. GT 1b patients on 12‐week regimens attained SVR rates of 194/196 (fibrosis F3) and 170/176 (cirrhosis). After a first year of provision of OP rD ± RBV with good adherence, high SVR rates were achieved in various patient subgroups and comorbidities.